NIPS

Natera Expects Further Growth in NIPT as it Expands Use Cases for Cancer, Transplant Tests

Natera Q3 Revenues Up 26 Percent on Increased Testing Volumes

Yourgene H1 Revenues Up 5 Percent

Centene Expands Coverage of Natera NIPT to All Pregnant Women

SVB Leerink Initiates Coverage of Natera With Outperform Rating

Natera Prices $250M Public Stock Offering

ACOG Guidelines Recommend NIPT for All Pregnancies Regardless of Risk

Progenity Asks Court to Declare Non-Infringement of Natera Patents

Natera Sues Progenity, Alleging Noninvasive Prenatal Test Infringes Patents

Natera and Illumina Settle Patent Suit, Sign License Agreement, Amend Supply Deal

Natera Q1 Revenues Grow 41 Percent

Yourgene Health Fiscal 2020 Revenues Up 86 Percent

Natera Prices $250M Senior Notes Offering

Natera Expects 35 Percent Rise in Q1 Revenues, Proposes $250M Senior Notes Offering

Natera Reports 19 Percent Increase in Q3 Revenues

FindGene Noninvasive Prenatal Screening Kit Gets Approval from Chinese Regulators

National Council on Disability Recommends More Regulation of NIPT